Literature DB >> 9422903

Comparison of the effects of isoflurane with those of propofol on pulmonary vascular impedance in experimental embolic pulmonary hypertension.

P Ewalenko1, S Brimioulle, M Delcroix, P Lejeune, R Naeije.   

Abstract

Inhaled but not i.v. anaesthetics are reported to decrease pulmonary vascular resistance. The aim of this study was to compare the effects of isoflurane with those of propofol on the interaction between right ventricular (RV) function and the pulmonary vascular system in embolic pulmonary hypertension. Nine dogs received in random sequence propofol 18 mg kg-1 h-1 and 1.4% end-tidal isoflurane. Pulmonary haemodynamic state was evaluated by pulmonary arterial pressure/flow (PAP/Q) plots and pulmonary vascular impedance (PVZ) spectra. Right ventricular function was assessed by total hydraulic power (Wtot), ratio of oscillatory power (Wosc) to Wtot, and dP/dtmax. Measurements were obtained, with both anaesthetics, before and after pulmonary embolic hypertension induced by autologous blood clots. Embolism increased PAP, 0 Hz and low frequency input impedance, displaced first minimum of PAP/Q moduli and zero crossing of phase to higher frequencies, decreased characteristic impedance, decreased Wosc/Wtot without affecting Wtot, and increased dP/dtmax. Compared with propofol, isoflurane at baseline did not affect PAP/Q plots, PVZ or hydraulic power data, but decreased dP/dtmax. After embolism, isoflurane shifted PAP/Q plots to lower PAP without affecting PVZ, did not affect hydraulic power data and decreased dP/dtmax. We conclude that in canine embolic pulmonary hypertension, isoflurane compared with propofol impeded RV vascular coupling caused by decreased RV contractility, while after-load remained unchanged despite some decrease in pulmonary vascular tone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9422903     DOI: 10.1093/bja/79.5.625

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  7 in total

1.  Physiologic changes in a nonhuman primate model of HIV-associated pulmonary arterial hypertension.

Authors:  M Patricia George; Hunter C Champion; Marc Simon; Siobhan Guyach; Rebecca Tarantelli; Heather M Kling; Alexandra Brower; Christopher Janssen; Jessica Murphy; Jonathan P Carney; Alison Morris; Mark T Gladwin; Karen A Norris
Journal:  Am J Respir Cell Mol Biol       Date:  2012-12-13       Impact factor: 6.914

2.  Pulmonary exposure to peat smoke extracts in rats decreases expiratory time and increases left heart end systolic volume.

Authors:  Leslie C Thompson; Yong Ho Kim; Brandi L Martin; Allen D Ledbetter; Janice A Dye; Mehdi S Hazari; M Ian Gilmour; Aimen K Farraj
Journal:  Inhal Toxicol       Date:  2019-01-15       Impact factor: 2.724

Review 3.  How to measure pulmonary vascular and right ventricular function.

Authors:  Naomi C Chesler; Alejandro Roldan; Rebecca R Vanderpool; Robert Naeije
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2009

4.  Effects of sevoflurane and propofol on right ventricular function and pulmonary circulation in patients undergone esophagectomy.

Authors:  Wen-Yun Xu; Na Wang; Hai-Tao Xu; Hong-Bin Yuan; Hai-Jing Sun; Chun-Li Dun; Shuang-Qiong Zhou; Zui Zou; Xue-Yin Shi
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

Review 5.  Pulmonary vascular mechanics: important contributors to the increased right ventricular afterload of pulmonary hypertension.

Authors:  Zhijie Wang; Naomi C Chesler
Journal:  Exp Physiol       Date:  2013-05-10       Impact factor: 2.969

6.  Pulmonary vascular wall stiffness: An important contributor to the increased right ventricular afterload with pulmonary hypertension.

Authors:  Zhijie Wang; Naomi C Chesler
Journal:  Pulm Circ       Date:  2011 Apr-Jun       Impact factor: 3.017

7.  Compensated right ventricular function of the onset of pulmonary hypertension in a rat model depends on chamber remodeling and contractile augmentation.

Authors:  Daniela Vélez-Rendón; Xiaoyan Zhang; Jesse Gerringer; Daniela Valdez-Jasso
Journal:  Pulm Circ       Date:  2018-09-03       Impact factor: 3.017

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.